Ahead of congressional hearings to discuss the recent price boost for the company’s, EpiPen product, Shah speculated that pharmaceutical company Mylan NV (NASDAQ:MYL) could be a buy.
On the morning before the hearing, Shah said that the bad news was already out there, and as a result the stock was hovering just above its 52-week low. He further said that the stock was likely to bounce back – and he would even be looking to buy if it dipped lower during the hearings.
Sure enough, the stock has tacked on 4.74% since.
Shah also discussed, Microsoft Corp. (NASDAQ:MSFT), Tesla Motors Inc. (NASDAQ:TSLA), the Bayer-Monsanto deal, December’s likely rate hike, and the politicization of the Fed.
